Implant improves vision for patients suffering from the leading cause of blindness in older Americans.
Physicians at the Virginia Commonwealth University Medical Center have become the first in Virginia to successfully implant a telescope in a patient’s eye to treat macular degeneration.
The telescope implant is designed to correct end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans. Patients with end-stage AMD have a central blind spot. This vision loss makes it difficult or impossible to see faces, to read and to perform everyday activities such as watching television, preparing meals and self-care.
William H. Benson, M.D., a cornea specialist and chairman of the Department of Ophthalmology at the VCU School of Medicine, performed the procedure.
“We are excited to provide this new surgical option to our advanced macular degeneration patients, who up until now have had limited options for improving vision,” Benson said. “Advanced macular degeneration is a devastating disease, which cannot be treated by any available drugs or surgical procedures. The telescope implant offers a new hope for patients with limited vision.”
Smaller than a pea, the telescope implant uses micro-optical technology to magnify images that would normally be seen in one’s “straight ahead” or central vision. The images are projected onto the healthy portion of the retina not affected by the disease, making it possible for patients to see or discern the central vision object of interest.
The Latest Bing News on:
Macular Degeneration
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- Revopsis raises funding to advance lead nAMD candidateon April 25, 2024 at 5:00 pm
Revopsis Therapeutics Inc. has closed its first seed funding round, raising $16.5 million that will fund the completion of ongoing IND-enabling studies with its lead candidate, RO-104, for the ...
- To Your Good Health: Over-the-counter eye drops safe to use with AMD medicationon April 25, 2024 at 7:15 am
I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). I have just had my second round of Eyelea, and with ...
- Dr. Roach: Over-the-counter eye drops safe to use with AMD medicationon April 24, 2024 at 5:00 pm
Dr. Roach: I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). I have just had my second round of Eyelea, and with the pollen starting up, my ...
- High dose aflibercept may be promising for treatment of age-related macular degenerationon April 24, 2024 at 2:55 pm
Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across treatment groups. Evidence Rating Level: 1 (Excellent) Study ...
- Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HDon April 24, 2024 at 8:29 am
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea ...
- AMD STOPPER Offers New Hope to Sufferers of Age-Related Macular Degenerationon April 23, 2024 at 9:50 am
AMD Stopper Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eye care researcher to treat Age-Related ...
- Restoring sight is possible now with optogeneticson April 23, 2024 at 3:31 am
Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired people.
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsighton April 22, 2024 at 2:31 pm
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
- Macular degeneration topic of Viroqua library programon April 18, 2024 at 12:30 pm
McIntosh Memorial Library, in partnership with the Vernon County Over 50 Club, are hosting a presentation with Dr. Troy McKay an optometrist with Gundersen Health System.
The Latest Google Headlines on:
Macular Degeneration
[google_news title=”” keyword=”Macular Degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Age-related macular degeneration
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- BCI maker Science acquires retinal implant from Pixium Visionon April 25, 2024 at 12:54 pm
Brain-computer interface developer Science Corporation acquired the IP and related assets for the Pixium Vision Prima implant.
- BrightFocus Foundation Announces $10M in New Funding Across Brain and Vision Research, Celebrates Historic Diversity of Grant Award Recipientson April 24, 2024 at 11:00 pm
Global nonprofit BrightFocus Foundation announces $10 million in new Alzheimer’s disease, macular degeneration, and glaucoma research grant funding—age-related diseases with no cure that affect more ...
- Over-the-counter eye drops safe to use with AMD medicationon April 24, 2024 at 10:30 pm
I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). I have just had my second round of Eyelea, and with the pollen starting up, my eyes are ...
- High dose aflibercept may be promising for treatment of age-related macular degenerationon April 24, 2024 at 2:55 pm
Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across treatment groups. Evidence Rating Level: 1 (Excellent) Study ...
- Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HDon April 24, 2024 at 8:29 am
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea ...
- AMD STOPPER Offers New Hope to Sufferers of Age-Related Macular Degenerationon April 23, 2024 at 9:50 am
AMD Stopper Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eye care researcher to treat Age-Related ...
- Restoring sight is possible now with optogeneticson April 23, 2024 at 3:31 am
Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired people.
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsighton April 22, 2024 at 2:31 pm
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
- Wet vs. Dry Macular Degeneration: What Is the Difference?on April 14, 2024 at 5:00 pm
Both types of age-related macular degeneration (AMD) can cause blurriness and visual changes. Dry AMD progresses slowly and causes permanent damage, while wet AMD is more severe but more treatable.
The Latest Google Headlines on:
Age-related macular degeneration
[google_news title=”” keyword=”age-related macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
